

References

L-28

1. Harris LN, Ismaila N, McShane LM, et al. Use of biomarkers to guide decisions of adjuvant systemic therapy for women with early stage invasive breast cancer: American Society of Oncology clinical practice guideline. *J Clin Oncol.* 2016; (34).
2. Holdenrieder S, Pagliaro L, Morgenstern D, Dayyani F. Clinically meaningful use of blood tumor markers in oncology. *BioMed Res Int.* 2016.
3. Aggarwal C, Thompson JC, Black TA, et al. Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer. *JAMA Oncol.* 2019;5(2):173-180.
4. Silvestri GA, Tanner NT, Kearney P, et al; PANOPTIC Trial Team. Assessment of plasma proteomics biomarker's ability to distinguish benign from malignant lung nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) trial. *Chest.* 2018;154(3):491-500.
5. Chu GCW, Lazare K, Sullivan F. Serum and blood based biomarkers for lung cancer screening: A systematic review. *BMC Cancer.* 2018;18(1):181.
6. Barr CE, Funston G, Mounce LTA, Pemberton PW, et al. Comparison of two immunoassays for the measurement of serum HE4 for ovarian cancer. *Pract Lab Med.* 2021;26:e00235.
7. Concors SJ, Sinnamon AJ, Ecker BL, Metz DC, et al. The impact of surgery for metastatic pancreatic neuroendocrine tumor: A contemporary evaluation matching for chromogranin a level. *HPB (Oxford).* 2020;22(1):83-90.
8. Campos-da-Paz M, Dórea JG, Galdino AS, Lacava ZGM, et al. Carcinoembryonic antigen (CEA) and hepatic metastasis in colorectal cancer: Update on biomarker for clinical and biotechnological approaches. *Recent Pat Biotechnol.* 2018;12(4):269-279.
9. Konishi T, Shimada Y, Hsu M, Tufts L, et al. Association of preoperative and postoperative serum carcinoembryonic antigen and colon cancer outcome. *JAMA Oncol.* 2018;4(3):309-315.
10. Hao WJ, Zhang H, Yu Y, Zhao J, et al. [Clinical significance and cost-benefit analysis of serum calcitonin assay in diagnosis and treatment of medullary thyroid carcinoma]. *Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi.* 2019;54(7):506-509.
11. Nash Z, Menon U. Ovarian cancer screening: Current status and future directions. *Best Pract Res Clin Obstet Gynaecol.* 2020;65:32-45.
12. Lin DC, Genzen JR. Concordance analysis of paired cancer antigen (CA) 15-3 and 27.29 testing. *Breast Cancer Res Treat.* 2018;167(1):269-276.

13. Aparicio J, Sánchez-Muñoz A, Ochendusko S, Gumà J, et al. Treatment and outcome of patients with stage I testicular cancer: A retrospective study from the Spanish germ cell cancer group. *J Urol*. 2019;202(4):742-747.
14. Fedorkova L, Ondrus D. Post-treatment persistent alpha-fetoprotein elevation in a patient with testicular cancer. *Klin Onkol*. 2021;34(1):56-58.
15. Hayes, Inc. Hayes Molecular Test Assessment. *Nodify CDT (Biodesix Inc.)*. Lansdale, PA: Hayes, Inc.; 04/20/2021.
16. Hayes, Inc. Hayes Molecular Test Assessment. *Nodify XL2 (Biodesix Inc.)*. Lansdale, PA: Hayes, Inc.; 05/13/2021.